Your shopping cart is currently empty

LAGIPRA peptide is a long-acting agonist of GIP1R. It improves insulin sensitivity by enhancing glucose handling and reduces circulating branched-chain amino acids (BCAA) and keto acids. LAGIPRA peptide holds potential for research in type 2 diabetes.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | LAGIPRA peptide is a long-acting agonist of GIP1R. It improves insulin sensitivity by enhancing glucose handling and reduces circulating branched-chain amino acids (BCAA) and keto acids. LAGIPRA peptide holds potential for research in type 2 diabetes. |
| In vivo | The LAGIPRA peptide, administered at 1000 nmol/kg subcutaneously, reduced hyperglycemia in Glp-1r–/– mice during an intraperitoneal glucose tolerance test but had no effect on Gipr–/– animals. At a dose of 300 nmol/kg subcutaneously, given once daily for 14 days, it slightly affected body weight (reducing it by 4%) and temporarily (within the initial 24-48 hours) reduced food intake, fasting glucose, and insulin levels. |
| Synonyms | Long acting GIPRA-1 |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.